Bismuth Subsalicylate Dosing for H. pylori Eradication in a 10-Year-Old Child
For a 10-year-old child undergoing H. pylori eradication therapy, bismuth subsalicylate should be dosed at 262 mg four times daily (QID) as part of a 14-day bismuth quadruple therapy regimen. 1
Recommended Regimen Structure
The complete 14-day bismuth quadruple therapy for this child should include:
- Bismuth subsalicylate: 262 mg QID (30 minutes before meals and at bedtime) 1
- Tetracycline: Cannot be used in a 10-year-old due to risk of tooth discoloration and bone growth alterations 2
- Alternative antibiotic approach: Consider amoxicillin 50 mg/kg/day in divided doses plus metronidazole 20 mg/kg/day 3
- PPI: Lansoprazole 1 mg/kg/day (maximum 30 mg daily) 3
Critical Age-Based Dosing Considerations
The 262 mg QID dose is specifically established for children ≤10 years of age, while children >10 years receive the higher adult dose of 524 mg (two tablets) QID 3, 2. Since this patient is exactly 10 years old, the lower pediatric dose of 262 mg QID is appropriate.
Practical Implementation
Timing is crucial: Administer bismuth subsalicylate 30 minutes before meals and at bedtime (four times daily), with antibiotics given 30 minutes after meals 1. This timing optimization maximizes drug absorption and efficacy.
Treatment duration: The full 14-day course is essential. While 10-day regimens exist for adults, pediatric data strongly support 14-day therapy for optimal eradication rates, which reached 92% in children using this approach 3.
Important Safety Caveats
- Reye's syndrome risk: Use bismuth subsalicylate with extreme caution if the child has any suspected viral infection, particularly influenza or varicella, due to the salicylate content 2
- Tetracycline restriction: The standard adult bismuth quadruple therapy includes tetracycline, but this is contraindicated in children under 8 years old and should be used cautiously even at age 10 2
- Alternative regimen: A sequential approach starting with PPI + amoxicillin for 7 days, followed by PPI + metronidazole + tetracycline + bismuth for days 8-14 achieved 92% eradication in children ≥8 years 3
Evidence Quality Note
The adult bismuth quadruple therapy guidelines 1 provide the dosing framework, but pediatric-specific evidence 3, 2 confirms the 262 mg QID dose for children ≤10 years. Recent pediatric data 4 also supports shorter 7-day bismuth-containing regimens (94% eradication), though 14-day therapy remains the established standard with the most robust evidence 3.
Monitor for adverse effects: Dark stools, tongue discoloration, and metallic taste are common but benign; gastrointestinal upset can be minimized by taking medications with food 5.